What is the appropriate action if a drug product is unauthorized during promotion?

Taking action through TPP's intervention is the appropriate course of action if a drug product is unauthorized during promotion. The term "TPP" likely refers to a regulatory body or authority, such as The Therapeutic Products Directorate in Canada, which oversees the safety, efficacy, and marketing of pharmaceuticals.

When a drug product is found to be unauthorized, it could pose significant risks to public health and safety. Regulatory bodies are entrusted to ensure that medical products adhere to rigorous standards before being made available to the public. Engaging TPP ensures that the issue is addressed following the appropriate legal and regulatory frameworks, which can include stopping the promotion, conducting investigations, and enforcing compliance with drug approval processes.

This choice demonstrates a proactive approach, prioritizing public safety and regulatory compliance, which is essential in the pharmaceutical industry to prevent the dissemination of misleading or potentially harmful information regarding drug products.